Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
76 hedge funds and large institutions have $56.8M invested in Oncternal Therapeutics, Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 28 increasing their positions, 22 reducing their positions, and 18 closing their positions.
111% more call options, than puts
Call options by funds: $1.86M | Put options by funds: $882K
27% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 22
10% less funds holding
Funds holding: 84 → 76 (-8)
13% less capital invested
Capital invested by funds: $65M → $56.8M (-$8.25M)
44% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$1.05M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$905K |
| 3 |
Millennium Management
New York
|
+$680K |
| 4 |
ECM
ExodusPoint Capital Management
New York
|
+$677K |
| 5 |
Renaissance Technologies
New York
|
+$375K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$1.37M |
| 2 |
ACM
Altium Capital Management
New York
|
-$818K |
| 3 |
JGC
J. Goldman & Co
New York
|
-$587K |
| 4 |
ACA
Apis Capital Advisors
New York
|
-$570K |
| 5 |
Two Sigma Investments
New York
|
-$415K |
ONCT Hedge Fund Activity: Q3 2021 in Review
76 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q3 2021, worth a combined $56.8M — down 13% from $65M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ONCT and 10 opened new positions — a net loss of 8 holders — while 22 trimmed existing stakes and 28 added.
The largest buyer was Morgan Stanley, adding an estimated $1.05M. The largest seller was Norges Bank, cutting an estimated $1.37M.
- 76 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q3 2021, down from 84 in Q2 2021.
- Funds reported $56.8M of Oncternal Therapeutics, Inc. Common Stock stock for Q3 2021, down 13% quarter-over-quarter.
- 10 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q3 2021 and 18 closed out, a net change of -8 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q3 2021 was Morgan Stanley, an estimated $1.05M added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q3 2021 was Norges Bank, an estimated $1.37M sold.
Based on aggregated 13F filings for Q3 2021.